Work

A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps1114

Authors: Leonel Fernando Hernandez-Aya, Feng Gao, Peter S. Goedegebuure, Cynthia X. Ma, Foluso Olabisi Ademuyiwa, Haeseong Park, Lindsay Leuthen Peterson, Nusayba Ali Bagegni, Ron Bose, William E. Gillanders

Institution: Washington University in St. Louis

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947299562

Cites:

Cited by: 10

Related to: 10